CYH33 clinical trials
CYH33 is named as an intervention in 2 current clinical trials in our China and Japan registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Haihe Biopharma Co., Ltd. The most-studied condition is PIK3CA-Related Overgrowth Spectrum (PROS).
How CYH33 works
All drug targets →- Clear cell adenocarcinomaPhase 2
- PIK3CA-related overgrowth spectrumPhase 1/2
- Pik3ca related overgrowth spectrumPhase 1/2
- Breast cancerPhase 1
- Cervical cancerPhase 1
- Endometrial cancerPhase 1
- Fallopian tube cancerPhase 1
- Head and neck squamous cell carcinomaPhase 1
- Ovarian cancerPhase 1
- Primary peritoneal carcinomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4800252, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12382, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for CYH33
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CYH33
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
NCT06975618 · ClinicalTrials.gov ↗ · PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
|
Phase 1/2 | Recruiting | Haihe Biopharma Co., Ltd | China, Japan |
|
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922 · ClinicalTrials.gov ↗ · Ovarian Cancer, Recurrent Cancer
|
Phase 2 | Active, closed | Haihe Biopharma Co., Ltd | China, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with CYH33
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Haihe Biopharma Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in Japan | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about CYH33 trials
How many clinical trials are testing CYH33?
2 current trials in our China and Japan registers name CYH33 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are CYH33 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CYH33 clinical trials?
The lead sponsor is Haihe Biopharma Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CYH33 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CYH33 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CYH33 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.